表柔比星连同多西紫杉醇实施三阴乳腺癌化疗的临床研究.docVIP

表柔比星连同多西紫杉醇实施三阴乳腺癌化疗的临床研究 　　摘要：目的 研究表柔比星连同多西紫杉醇作为新辅助化疗方案对三阴乳腺癌（TNBC）的临床效果。方法 抽选84例乳腺癌患者为此次研究观察对象，根据是否为三阴乳腺癌将患者分为对照组（非TNBC）与观察组（TNBC）各42例，两组均接受表柔比星连同多西紫杉醇（ET方案）化疗， 具体为表柔比星与多西紫杉醇（ET方案）：静脉滴注表柔比星90 mg/m2，d1，静滴多西紫杉醇75 mg/m2，以21 d为1个疗程。在完成化疗周期后16～20 d采取手术治疗，疗效的评估则在术前1～2 d进行。比较两组临床疗效的差异。?Y果 研究组的完全缓解率为50.00%相比较于对照组的26.20%显著更高（P0.05），且临床总缓解率为85.70%相比较于对照组的66.70%显著更高（P0.05）。结论 三阴乳腺癌采取表柔比星连同多西紫杉醇作为新辅助化疗方案可获得更高的完全缓解率与总缓解率，疗效显著，建议临床加以推广。 　　关键词：表柔比星；多西紫杉醇；三阴乳腺癌 　　中图分类号：R737.9 文献标识码：A 文章编号：1006-1959（2017）14-0072-03 　　Clinical Study of Epirubicin Combined with Docetaxel in the Treatment of Three Negative Breast Cancer Chemotherapy 　　LI Qi-ju 　　（Department of Oncology，the First Peoples Hospital of Liangshan Yi Autonomous Prefecture，Xichang 615000，Sichuan，China） 　　Abstract：Objective To study the epirubicin and docetaxel as neoadjuvant chemotherapy on three negative breast cancer（TNBC）clinical effect. Methods 84 cases of breast cancer were selected as the study object，according to whether the three negative breast cancer patients were divided into control group（non TNBC）and observation group（TNBC=42），two groups were treated with docetaxel and epirubicin（ET regimen）chemotherapy，specific to epirubicin and docetaxel（ET）：intravenous injection of epirubicin 90 mg/m2，d1，intravenous docetaxel 75 mg/m2，21 d for 1 courses.Surgery was performed 16 to 20 d after the completion of the chemotherapy cycle.The evaluation of the curative effect was performed 1 to 2 d before surgery. Comparison of the two groups of clinical efficacy differences.Results The complete remission rate was 50.00% compared with 26.20% in the control group were significantly higher（P0.05），and the total clinical response rate was 85.70% compared with 66.70% in the control group were significantly higher（P0.05）.Conclusion Three negative breast cancer by epirubicin and docetaxel as neoadjuvant chemotherapy can get a higher complete remission rate and total remission rate，obvious curative effect，it is suggested that clini